Aptimmune
St Louis
About Aptimmune
Aptimmune is a biotechnology company that focuses on developing a muscoal vaccine against viral diseases swine. It focuses on swine vaccines and the prevention of two major diseases, Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and influenza. It utilizes novel technologies to create effective nasal delivery vaccines against PRRSV such as the proprietary pig alveolar macrophage cell line ZMAC. The company was founded in 2010 and headquartered in St. Louis, Missouri.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $8.8M
- Last round: Convertible Note (Jan 2022)
- Website: aptimmune.com
- Phone: (314) 736-4488
Industries & Categories
Biopharma, Biotechnology, Health Care, Health Diagnostics, Test and Measurement
Social Profiles
Canonical: https://fsome.com/organization/aptimmune-14607 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.